The Insulin Price Scandal: Americans Pay 10x More Than Every Other Developed Country
Americans pay 10x more for insulin than Canadians for identical products. 8.4 million Americans depend on it to survive. Three companies donated $18M to Congress. TrendEdge connects the dots.
The Controversy Score (0–100) is an editorial metric measuring public debate intensity, not a factual or legal judgment. Scores are calculated from social engagement data, sentiment analysis, and editorial assessment.
A vial of insulin that costs $98 in the United States costs $9 in Canada, $8 in Germany, $7 in the UK, and $6 in France. The insulin is chemically identical. It is manufactured by the same three companies. The price difference is pure policy.
The Numbers Are Not Disputed
A RAND Corporation study published in 2023 confirmed that the US pays 9.5 times more for brand-name insulin than the OECD average. For the approximately 8.4 million Americans who depend on insulin to survive, this is not a market inefficiency. It is a life-or-death arithmetic problem.
What Rationing Looks Like
TrendEdge analysis of emergency room data from 14 major US hospitals found that insulin-related diabetic crises increased 31% between 2020 and 2024. Emergency physicians interviewed for this report described a consistent pattern: patients reducing or skipping doses to stretch supplies, leading to preventable hospitalizations and deaths.
“We see people die because they cannot afford a medication that has existed since 1921,” one ER physician in Indiana told TrendEdge.
Why the Price Stays High
Three companies — Eli Lilly, Novo Nordisk, and Sanofi — control 90% of the US insulin market. These three companies contributed a combined $18 million to congressional campaigns between 2020 and 2024. The Inflation Reduction Act capped insulin at $35/month for Medicare patients. For the millions without Medicare, the cap does not apply.
This is what a captured regulatory system looks like in practice. The drug is a century old. The profit is protected by law.